Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen
- PMID: 21092280
- PMCID: PMC3001414
- DOI: 10.1186/1742-6405-7-40
Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen
Abstract
Background: Vitamin D is an important determinant of bone health and also plays a major role in the regulation of the immune system. Interestingly, vitamin D status before the start of highly active antiretroviral therapy (HAART) has been recently associated with HIV disease progression and overall mortality in HIV-positive pregnant women. We prospectively studied vitamin D status in HIV individuals on HAART in Belgium.We selected samples from HIV-positive adults starting HAART with a pre-HAART CD4 T-cell count >100 cells/mm3 followed up for at least 12 months without a treatment change. We compared 25-hydroxyvitamin D plasma [25-(OH)D] concentration in paired samples before and after 12 months of HAART. 25-(OH)D levels are presented using two different cut-offs: <20 ng/ml and <30 ng/ml.
Results: Vitamin D deficiency was common before HAART, the frequency of plasma 25-(OH)D concentrations below 20 ng/ml and 30 below ng/ml was 43.7% and 70.1% respectively. After 12 months on HAART, the frequency increased to 47.1% and 81.6%.HAART for 12 months was associated with a significant decrease of plasma 25-(OH)D concentration (p = 0.001). Decreasing plasma 25-(OH)D concentration on HAART was associated in the multivariate model with NNRTI-based regimen (p = 0.001) and lower body weight (p = 0.008). Plasma 25-(OH)D concentrations decreased significantly in both nevirapine and efavirenz-containing regimens but not in PI-treated patients.
Conclusions: Vitamin D deficiency is frequent in HIV-positive individuals and NNRTI therapy further decreases 25-(OH)D concentrations. Consequently, vitamin D status need to be checked regularly in all HIV-infected patients and vitamin D supplementation should be given when needed.
Figures
Similar articles
-
Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy.AIDS Res Hum Retroviruses. 2008 Nov;24(11):1375-82. doi: 10.1089/aid.2008.0058. AIDS Res Hum Retroviruses. 2008. PMID: 18928396
-
Vitamin D Insufficiency/Deficiency in HIV-Infected Inner City Youth.J Int Assoc Provid AIDS Care. 2014 Sep-Oct;13(5):438-42. doi: 10.1177/2325957413495566. Epub 2013 Jul 23. J Int Assoc Provid AIDS Care. 2014. PMID: 23881908
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.Pediatrics. 2002 Feb;109(2):E25. doi: 10.1542/peds.109.2.e25. Pediatrics. 2002. PMID: 11826235
-
Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses.Lancet. 2006 Oct 28;368(9546):1503-15. doi: 10.1016/S0140-6736(06)69638-4. Lancet. 2006. PMID: 17071284 Review.
Cited by
-
Evaluation of Adherence to Guideline-Based Bone Mineral Density Screening in Veterans with HIV.AIDS Res Hum Retroviruses. 2022 Mar;38(3):216-221. doi: 10.1089/AID.2021.0095. Epub 2022 Jan 24. AIDS Res Hum Retroviruses. 2022. PMID: 34969257 Free PMC article.
-
Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.BMC Musculoskelet Disord. 2013 Jul 30;14:224. doi: 10.1186/1471-2474-14-224. BMC Musculoskelet Disord. 2013. PMID: 23899016 Free PMC article.
-
Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study.BMC Infect Dis. 2013 Jun 28;13:293. doi: 10.1186/1471-2334-13-293. BMC Infect Dis. 2013. PMID: 23809140 Free PMC article. Clinical Trial.
-
Effects of cholecalciferol supplementation on serum and urinary vitamin D metabolites and binding protein in HIV-infected youth.J Steroid Biochem Mol Biol. 2017 Apr;168:38-48. doi: 10.1016/j.jsbmb.2017.01.018. Epub 2017 Feb 1. J Steroid Biochem Mol Biol. 2017. PMID: 28161530 Free PMC article. Clinical Trial.
-
Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modelling of 25-hydroxycholecalciferol.Br J Clin Pharmacol. 2013 May;75(5):1312-20. doi: 10.1111/bcp.12006. Br J Clin Pharmacol. 2013. PMID: 23072545 Free PMC article.
References
-
- Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820–825. - PubMed
-
- Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zugel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–1773. doi: 10.1126/science.1123933. - DOI - PubMed
-
- Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159–1165. doi: 10.1001/archinte.167.11.1159. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous